Digital Diagnostics Founder Co-Authors Study on Addressing Autonomous AI Concerns
Coralville, Iowa November 14, 2023 — Michael D. Abràmoff, MD, PhD, founder, and executive chairman of Digital Diagnostics, creator of the LumineticsCore™ AI system for diagnosing diabetic retinopathy, has authored a peer-reviewed study that discusses autonomous AI systems in healthcare and the necessity of evolved liability, regulation, and cost considerations. Titled Autonomous AI systems in the face of liability, regulations and costs, the study was co-authored by experts from Stanford University and Harvard University and published by the National Library of Medicine National Center for Biotechnology Information.
The study focuses on the changing landscape for autonomous AI in healthcare and offers possible solutions for some of the largest areas of concern, such as medical liability and malpractice, regulation of autonomous AI systems, and payment models.
“Autonomous AI has huge potential to streamline workflows, handle language-related tasks, and ultimately free doctors to focus more intently on the human aspects of healthcare. However, there are still concerns that need to be addressed from an ethical framework to fully integrate autonomous AI into healthcare and ensure continued and widespread stakeholder support,” said Dr. Abramoff. “The intent of this research is to bring attention to these critical focus areas while also offering specific examples of solutions, such as liability as a means of facilitating increased access to high-quality innovation to improve patient experience and outcomes.”
The publication discusses the potential for autonomous AI to reduce waste and improve patient outcomes and health equity as the availability of such systems increases for a variety of tasks within healthcare. To work toward the widespread acceptance of autonomous AI among healthcare practices and providers, the study argues that there must be a concerted effort to ensure the ethical and safe development of autonomous AI models in addition to establishing robust monitoring that is designed to consider the unique capabilities of AI systems.
Read the full paper: Autonomous AI systems in the face of liability, regulations, and costs
About Digital Diagnostics
Digital Diagnostics Inc. is a pioneering AI diagnostics company on a mission to transform the quality, accessibility, equity, and affordability of global health care through the application of technology in the medical diagnosis and treatment process. The company, originally founded by Michael D. Abramoff, MD, PhD, a neuroscientist, practicing fellowship-trained retina specialist, and computer engineer, is led by him and co-founders John Bertrand and Seth Rainford.
Digital Diagnostics is paving the way for autonomous and assistive AI technology that is free of bias to become a new standard of care, contributing to democratizing health care and closing care gaps. The company works closely with patient advocacy groups, provider organizations, regulators, and other quality of care and ethics-focused stakeholders to enable the adoption of health care AI. For more information and the latest news follow: https://www.digitaldiagnostics.com/